Sugi Predict

Sugi Predict / Compounds / SCHEMBL1459953

SCHEMBL1459953

SCHEMBL1459953

COC(=O)c1cc(C)c(Br)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.47
▸ LCK P06239 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MAPT P10636 4/20 0.43
▸ GABRP O00591 2/20 0.43
▸ GABRD O14764 2/20 0.43
▸ GABRA1 P14867 2/20 0.43
▸ GABRB1 P18505 2/20 0.43
▸ GABRG2 P18507 2/20 0.43
▸ GABRB3 P28472 2/20 0.43
▸ GABRA5 P31644 2/20 0.43
▸ GABRA3 P34903 2/20 0.43
▸ GABRA2 P47869 2/20 0.43
▸ GABRB2 P47870 2/20 0.43
▸ GABRA4 P48169 2/20 0.43
▸ GABRE P78334 2/20 0.43
▸ GABRA6 Q16445 2/20 0.43
▸ GABRG1 Q8N1C3 2/20 0.43
▸ GABRG3 Q99928 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22978646 0.86 MAPK1 (0.47) MAPK1LCKKDM4EL3MBTL1MAPT
SCHEMBL31161438 0.86 MAPK1 (0.47) MAPK1LCKKDM4EL3MBTL1MAPT
SCHEMBL18825226 0.85 MAPK1 (0.53) MAPK1LCKKDM4EL3MBTL1MAPT
SCHEMBL1179347 0.83 GABRA1 (0.50) KDM4EMAPTGABRPGABRDGABRA1
SCHEMBL4807973 0.82 MAPK1 (0.47) MAPK1LCKKDM4EL3MBTL1MAPT
SCHEMBL9400422 0.82 MAPK1 (0.47) MAPK1LCKKDM4EL3MBTL1MAPT
SCHEMBL23611991 0.82 LCK (0.53) MAPK1LCKKDM4EL3MBTL1MAPT
SCHEMBL25087495 0.81 GABRG2 (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL23481999 0.81 MAPK1 (0.50) MAPK1LCKKDM4EL3MBTL1MAPT
SCHEMBL18340557 0.81 MAPK1 (0.46) MAPK1LCKKDM4EL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 — — US disclosed
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist BEONE MEDICINES I GMBH (CH) 2026-04-28 — — US disclosed
WO-2025096957-A1 RAS-PI3K INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2025-05-08 — — WO disclosed
CN-113423708-B Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists 百济神州有限公司 2025-04-22 — — CN disclosed
CN-113710668-B Condensed azines for EP300 or CBP modulation and indications thereof OPNA生物公司 2025-01-07 — — CN disclosed
US-20240368122-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS INC (US) 2024-11-07 — — US disclosed
US-20240287062-A1 NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-08-29 — — US disclosed
EP-4387964-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-06-26 — — EP disclosed
CN-118119629-A Nitrogen-containing heterocyclic compound and medical application thereof 中国医药研究开发中心有限公司 2024-05-31 — — CN disclosed
US-20130109649-A1 FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR MERCK SHARP & DOHME LLC 2013-05-02 — — US disclosed
WO-2013063217-A1 FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR MERCK SHARP & DOHME CORP. (US) 2013-05-02 — — WO disclosed
WO-2012143329-A1 TRIAZOLOPYRIDINES BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-10-26 — — WO disclosed
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 — — EP disclosed
CN-102574788-A Indole derivatives as crac modulators HOFFMANN LA ROCHE 2012-07-11 — — CN disclosed
WO-2012058187-A1 CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR MERCK SHARP & DOHME CORP. (US) 2012-05-03 — — WO disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 — — WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 — — US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 — — US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368122-A1 JAK2 INHIBITORS AND METHODS OF USE THEREOF JAK2, JAK1, JAK3 MAPK1 590/4885LCK 33/4885KDM4E 1108/4885
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E MAPK1 2352/4885LCK 1316/4885KDM4E 2583/4885
US-12612407-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist TLR7, TLR8, TLR1 MAPK1 537/4885LCK 413/4885KDM4E 2199/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR MAPK1 4489/4885LCK 3084/4885KDM4E 3829/4885
US-20130109649-A1 FUSED BICYCLIC OXAZOLIDINONE CETP INHIBITOR CETP, MTTP, APOB MAPK1 3394/4885LCK 3867/4885KDM4E 2743/4885
US-20240287062-A1 NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES BRAF, NRAS, ABL1 MAPK1 228/4885LCK 66/4885KDM4E 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.